

## Amendments

### In the specification:

Please delete pages 19-21 of the translation of the specification filed herewith, which constitute a translation of the sequence listing, and substitute therefor new pages 19-23 appended hereto, which constitute a substitute Sequence Listing. Please renumber the pages of claims beginning with page number 24.

### In the claims:

Please amend claims 2, 5, and 7 and add new claim 8 as shown below:

2. (Amended) A method for producing the recombinant conglutinin of claim 1 [comprising a native conglutinin fragment] comprising the steps of:

(a) preparing a vector inserted there into cDNA corresponding to 613 bp through 1113 bp of the native conglutinin DNA,

(b) obtaining transformants by introducing said vector into *Escherichia coli* JM109,

(c) incubating said transformants in an appropriate medium,

(d) infecting said incubated transformants with phage, and

(e) collecting recombinant conglutinin from the phage-infected transformants,

wherein said recombinant conglutinin comprises a collagen region having two units of amino acids sequence of Gly-Xaa-Xaa (SEQ ID NO. 3), a neck region of the native conglutinin and a carbohydrate recognition domain of the native conglutinin, and 2<sup>nd</sup> and 3<sup>rd</sup> amino acids in said amino acid sequence of Gly-Xaa-Xaa are protein-constituting amino acid.

5. (Amended) The method for detecting the anti-virus activity according to [the] claim 3 [or 4] wherein said virus is Influenza A virus.

7. (Amended) Human Mannan-binding protein (hMBP) according to claim 6 having anti-Influenza A virus activity.